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INTRODUCTION: 
 
Uterine fibroids mainly occur in 30 % of women over 30 years in their 
reproductive age causing severe personal, social and economic problems.
1
 These 
fibroids are mostly asymptomatic, but women approach medical facilities with 
symptoms of menorrhagia, pain during cycles, pressure symptoms (increased 
frequency of micturition, constipation and nocturia), infertility and problems with 
pregnancy.
2
 
 
Since many years the most common form of therapy for uterine leiomyomas 
has been hysterectomy and occasionally myomectomy. THE OPTION FOR 
WOMEN ALL THESE YEARS WAS STARK: EITHER TO SUFFER WITH 
THE INTENSE DISCOMFORT OR ENDURE MAJOR SURGERY. Of latest, 
many conservativeoptions instead of hysterectomy and myomectomy have been 
introduced.
3
 Among them the most accepted and admired are hysteroscopic 
myomectomy and uterine artery embolization. These have certain limitations 
9 
 
 
regarding the size of the fibroids and the requirement for general anesthesia. (Fig1)
 
Fig 1: Comparing the various choices of treatment for uterine leiomyomas by 
extent of invasiveness. 
28 
 
 
  Uterine artery embolization (UAE) has become a gold standard conventional 
interventional procedure for treating symptomatic fibroids.
12  
However it has 
certain complications like pain after procedure and Post Embolization syndrome.
4 
Minimally invasive percutaneous treatments using thermal ablation procedures 
have also been introduced. Treatment of uterine leiomyomas with radiofrequency 
ablation 
13
, cryoablation 
14,15
 , and laser therapies
16
 have been reported. 
10 
 
 
Since many years, the interaction of ultrasound energy with body tissues has 
been utilized. As early as 1927, it was recognized that ultrasound energy could 
cause a rise in tissue temperature, and it was applied therapeutically rather than as 
a diagnostic modality.
5
 
 The energy level of ultrasound is very high such that when focused to a 
target tissue at a point it leads to protein denaturation and tissue necrosis with a 
temperature greater than 55
o 
C.
6 
Magnetic resonance guided high intensity focused ultrasound (MRgFUS ) 
therapy of fibroids is a proven technique approved by US Food and Drug 
administration for treatment of leiomyomas by heat generated using high intensity 
focused ultrasound.
4 
Benefits of MRgFUS are as follows: rapid relief from symptoms of uterine 
leiomyomas, speedy recoverytimes, very rare post-operative complications in 
comparisonwith UAE or hysterectomy, andvery rare occurrence of adverse 
effects.
17 
It can improve fibroid related symptoms and cause shrinkage of fibroids in 
due course of time. The aim of this study is to evaluate the clinical efficacy of this 
procedure in patients with symptomatic fibroids using clinical symptom severity 
scoring (SSS) before the procedure and after 6 to 12 months follow up. 
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AIM OF THE STUDY: 
 
TO STUDY THE EFFECTIVENESS OF MAGNETIC RESONANCE 
GUIDED HIGH INTENSITY FOCUSED ULTRASOUND IN THE 
TREATMENT OF SYMPTOMATIC UTERINE LEIOMYOMAS IN 
TERMS OF CLINICAL IMPROVEMENT. 
 
OBJECTIVE: 
WHETHER MRgFUS CAN BE CONSIDERED AS A PRIMARY MODE OF 
NONINVASIVE TREATMENT OF UTERINE FIBROIDS. 
 
PRIMARY OUTCOME:  
 
 THE DEGREE OF SYMPTOM RELIEF AFTER THE PROCEDURE AT 6 
MONTHS. 
 THE IMPROVEMENT IN HEMATOCRIT. 
 THE MEAN FIBROID SHRINKAGE AT 6 MONTHS AFTER THE 
PROCEDURE AND TO CORRELATE IT WITH THE IMMEDIATE 
NONPERFUSED VOLUME RATIO. 
  ANY ADVERSE EFFECTS RELATED TO THE PROCEDURE. 
13 
 
 
 
SECONDARY OUTCOME: 
 
 THE DEGREE OF SYMPTOM RELIEF AT 12 MONTHS. 
 THE REQUIREMENT OF ANY ADDITIONAL PROCEDURE. 
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REVIEW OF LITERATURE: 
 
1. Lele in 1975, described that ultrasound waves are suited for the tissues in 
depth because of their higher penetrating capacity through soft tissue than infrared 
and laser beams.
6
 
―Focused ultrasound technology fulfillsprerequisites of aperfect surgical tool. It 
has the established capacity to damage the selected targets situated deep within 
tissue without affecting the tissue in the path or those around the lesions.‖ 
2. Hynynen et al. elaborated thesubstantial potential of this technology 
combination, andtheir theory was supported with results obtained from testing in 
animals.
26
 
3. Cline and Jolesz et al in 1995..The authors concluded that with the 
guidance of  Imaging ,defining target  accuracy and control for thermal therapy in a 
variety of tissues with various rates of perfusion could be accomplished with 
precise thermal imaging feedback.
23 
4. Hyun S. Kim,et al concluded that long term results were acceptable because 
long term follow up of patients treated with HIFU showed good relief of symptoms 
which was sustained. 
4
. 
5. Jonathan Hindley et al conducted a study on early results and concluded on 
follow up that symptomatic improvement was significant in 79.3% of patients who 
were treated. The average fibroid volume shrinkage at 6 months was 13.5%, but 
16 
 
 
non enhancing volume (mean, 51 cm3) remained within the treated fibroid at 6 
months. 
3 
6. Summia Zaher et al studied patient suitability for MRgFUS-
moderationmethodspermitfor less restraining MRgFUS selection criteria for 
therapyfor symptomatic uterine leiomyomas and are anticipated to enlarge the pool 
of patients. 
7. Rabinovici et al, concluded that earliest pregnancy experience after HIFU 
treatment has been promising, with an increased rateof delivered and continuing 
  pregnancies. (Fertil Steril2010;93:199–209). 
8. Krzysztof R. Gorny,Elizabeth A. Stewart et al. evaluated 12 month 
outcome and concluded that MR-guided focused US is an innovative noninvasive 
mode of  therapy   for uterine leiomyomas  that  can be used successfully and 
without any harm to treat uterine fibroids  and brings about noteworthy sustained 
symptom relief that lasts  at least for one year. 
The incidence of additional procedures for persistent symptoms during the study 
was analogous to those in earlier studies of uterine artery embolization.  
9. Suzanne D. LeBlang conducted a study to evaluate the amount of fibroid 
ablation and shrinkage after MRI-guided high intensity focused ultrasound therapy 
 
17 
 
 
 and the outcomes revealed that the meanNonperfused volume ratio was 55% ± 
25% soon after treatment with mean fibroid volume shrinkage of 31% ± 28%.
39
 
11. Taran et al. organized and conducted a study comparing the most  
conventional treatment for uterine leiomyomas, hysterectomy and MRgFUS in a 
matched group of patients selected contemporaneously. The non-invasive, 
outpatient MRgFUS procedure was linked with very few  adverse events both 
during and after the procedure in contrast with surgical hysterectomy. Similarly, 
patients treated with MRgFUS recovered faster and returned to work the next day, 
and the loss of work days was only one day for HIFU, whereas it was six weeks for 
hysterectomy. The symptomatic relief lasted longer in proportion to the percentage 
of ablation of the fibroid which corresponds to the Non Perfused Volume ratio.
34
 
12. Okada et al confirmed in his study that the symptomatic outcome can be 
improved by ablating larger areas of the leiomyoma. They also proved that 
obtaining a greater NPV ratio is safe and to achieve the maximum treatment 
response, this must be the goal of treatment.
36
 
13. Funaki et al. presented that the character of fibroids on MR imaging bears a 
great influence on the outcome. Fibroids with Low-intensity T2 signal 
respondsimmensely well, and hence larger areas of destruction are produced 
resulting in larger NPV ratios. On the contrary, T2 signal high intensity fibroids do 
not respond well and outcome is not achieved as desired.
44 
18 
 
 
14. Elizabeth A. Stewart, Amy K. O’Sullivan et al studied regarding cost-
effectiveness and their findings suggest that MRgFUS is in the range of presently 
acknowledged standards for cost-effectiveness, end to end with hysterectomy and 
uterine artery embolization. 
15. Researchers who participated in the clinical trials condensed their opinion of 
MRgFUSas given below: 
―Weconsider that MRgFUS therapy offers a potentially noteworthy novel 
noninvasive and valuable therapy for uterine leiomyomas, specifically in patients 
who request to keep away from invasive or agonizing therapies. The deprivation of 
invasiveness in MRI-guided focused ultrasoundtreatment rendersit remarkably 
fascinating and charismatic. We also emphasize that MRI-guided focused 
ultrasound treatment  for leiomyomas  might ascertain to be acrucial model for the 
expansion of this noninvasive, meticulous, well regulated and planned, tissue 
ablating technology to many other diseases‖. 
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OVERVIEW 
UTERINE LEIOMYOMA 
Uterine leiomyomas are benign smooth muscle neoplasms that classically arise 
from the myometrium. They are frequently referred to as uterine fibroids and 
because their considerable collagen content creates a fibrous consistency, they are 
incorrectly called fibroids. Fibroids can be as small as a pea and can grow to 
become as large as a pregnancy at term. 
Incidence is generally 20-25% in reproductive age group women. But has been 
shown to be as high as 70-80% as per histopathology or by ultrasoundexamination. 
In many women, fibroids are clinicallyimmaterial. On the contrary, their number, 
size or location within the uterus can provoke a variety of symptoms. Of all 
inpatient hospitalizations, fibroids comprise 27% of gynecologic admissions.  
Fibroids are benign monoclonal tumors of the smooth muscle cells of the 
myometrium and comprise of larger clusters of extracellular matrix composed of 
collagen, elastin, fibronectin and proteoglycans. 
 
ETIOLOGY OF FIBROIDS: 
GENETICS: They are monoclonal and about 40% have chromosomal 
abnormalities that include translocations between chromosome 12 and 14, 
deletions of chromosome 7, trisomy of chromosome 12. 
21 
 
 
HORMONAL INFLUENCES: Both estrogen and progesterone seem to favor the 
growth of fibroids. Fibroids are seldom detected before puberty and are most 
predominant among women of the reproductive age group, revert as they 
attainmenopause. Obesity and early menarche increase overall lifetime exposure to 
estrogen and increase the incidence. When estrogen exposure is less, as found with 
smoking, exercise and increase parity, it is protective. As a result of increased 
levels of aromatase activity within fibroids, de novo production of estradiol is 
higher than in normal myometrium. Fibroids have increased concentrations of 
progesterone receptors and thus progesterone is also important in the pathogenesis. 
GROWTH FACTORS: Growth factors lie Transforming Growth Factor-β, 
Fibroblast growth factor increase smooth muscle proliferation. Vascular 
Endothelial Growth Factor promotes angiogenesis and stimulates synthesis of 
extracellular matrix. These factors are produced locally by smooth muscle cells 
and fibroblasts. 
RISK FACTORS: 
AGE: The incidence gradually increases with age. At 20 to 30 years, the incidence 
is only 0.31 per 1000 women years but by ages 45 to 50, incidence increases 20 
fold to 6.2 per 1000 women years
19
. 
Endogenous hormonal factors:Greater exposure to estrogen as found with early 
menarche and late menopause decreases likelihood of having fibroids. 
22 
 
 
Polycysticovarian syndrome increases the exposure to estrogen and thus increases 
likelihood of fibroids
19
. 
FAMILY HISTORY: First degree relatives have 2.5 times increased riskof 
acquiring fibroids. 
ETHNICITY: African American women have a 2.9 times greater risk of having 
fibroids than white women. 
WEIGHT: Risk of fibroids increased 21% with each 10 kg increase in 
bodyweight. 
DIET: Diet rich in beef, red meat increases the incidence. Diet rich in green 
vegetables decrease the risk. 
EXERCISE: Women in highest category of physical activity (7 hours per week) 
are less likely to have fibroids. 
PARITY: Increasing parity decreases the incidence of fibroids.The remodeling 
process of the postpartum myometrium including apoptosis and differentiation may 
be responsible for the involution of fibroids. Moreover vessels supplying fibroids 
regress during involution of uterus
20
. 
SMOKING: Nicotine inhibits aromatase and thus reduces conversion of 
androgens to estrogens. 
23 
 
 
TISSUE INJURY: Repetitive tissue injury to the endometrium and endothelium 
might promote the development of monoclonal smooth muscle proliferations in the 
muscular wall due to release of several growth factors. 
CLINICAL PRESENTATION: 
Fibroids are certainly not coupled with mortality but they might lead to morbidity 
and appreciably affect the quality of life. Most uterine myomas cause no 
symptoms. It is estimated that only 20 to 50% of women suffer from symptoms. 
The symptoms generally correlate with their location, number, size or concomitant 
degenerative changes
20
. They may present as follows: 
 Asymptomatic 
 Abnormal uterine bleeding-menorrhagia, anemia. 
 Pelvic mass with pressure symptoms 
 Urinary frequency, incontinence, hydronephrosis, constipation, tenesmus. 
 Pelvic pain 
 Reproductive dysfunction-Infertility. 
 Pregnancy related-myoma growth, red degeneration and pain, spontaneous 
miscarriage. 
 Malignancy very rarely. 
24 
 
 
ABNORMAL BLEEDING: About 46% of women with fibroids report gushing of 
blood during menstrual periods. Gushing of blood and duration of periods were 
correlated with the size of fibroids. 
PELVIC PAIN/DYSMENORRHEA: Dysmenorrhea may be present when there is 
increased flow but pain as a symptom of fibroid is not frequent. 
PRESSURE SYMPTOMS: As tumors grow pressure is exerted on the adjacent 
organs like urinary tract and recto sigmoid and thus symptoms like frequency, 
urgency, constipation, and tenesmus occur. 
 
 
DIAGNOSTIC IMAGING: 
TRANSVAGINAL ULTRASOUND: The efficacy is highly operator dependent 
and varies from 65 to 95%.The mapping accuracy decrease in larger uteri and with 
multiple fibroids.The addition of sonohysterography to TVUS greatly improves the 
sensitivity to 90%. 
MRI: The most accurate imaging modality for the diagnosis, mapping and 
characterization of leiomyomas.Nondegenerated fibroids appear with low signal 
intensity. 
25 
 
 
FIGO FIBROID CLASSIFICATION
19
:
 
 
Sub mucosal 
  0-intracavitary pedunculated 
 1- <50% intramural 
 2- >50% intramural 
Others 
 3-Abuts the endometrium without intracavitary component. 
 4-Intramural and entirely within the myometrium without extension to 
either endometrial surface or to serosa. 
 5-subserosal at least 50% intramural 
26 
 
 
 6-subserosal <50% intramural 
 7-subserosal attached to serosa by a stalk. 
 8-no involvement of myometrium, includes cervical lesions, those in the 
round or broad ligaments without direct attachment to uterus and 
parasitic fibroids. 
 
MANAGEMENT: 
It is estimated that 25 to 40% of women in reproductive age group are affected by 
fibroids.The malignant potential of fibroids is <1% and thus the main aim of 
treatment is to provide relief of symptoms and improve quality of life, Small and 
asymptomatic fibroids don‘t need treatment and can be observed every 6 months. 
INDICATIONS FOR TREATMENT
21
: 
 Infertility caused by corneal fibroid blocking tubes, habitual abortion due to 
sub mucous fibroid. 
 Fibroid more than 12 weeks size and a pedunculated fibroid. 
 Asymptomatic fibroid causing pressure on the ureter leaving residual urine 
and infection. 
 Rapidly growing fibroid in a menopausal woman. 
 All symptomatic fibroids require treatment. 
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TREATMENT MAY BE: 
 Watchful waiting. 
 Conservative line of management. 
 Definitive management. 
 Recent advances. 
WATCHFUL WAITING: Not having treatment seldom ends in any damage, apart 
from patients with severe fibroid related menorrhagia leading to anemia or 
hydronephrosis from ureteric obstruction due to a massively enlarged fibroid 
uterus. Thus, as women approach menopause watchful waiting may be considered, 
because there is limited time to develop new symptoms and after menopause 
bleeding stops and fibroids decrease in size
21
.  
CONSERVATIVE LINE OF MANAGEMENT: 
Conservative line of management for fibroids includes 
 Medical management and 
 Minimally invasive surgeries. 
MEDICAL TREATMENT: 
Available options are 
 LNG-IUS(MIRENA), 
 GnRH Analogues 
 RU-486 
28 
 
 
 Danazol 
The above drugs have been used to treat fibroid associated menorrhagia and pain 
with limited success. 
Recent advances in medical therapy include aromatase inhibitors like 
Fadrazole, Selective estrogen receptor modulators like Raloxifene, Selective 
progesterone receptor modulators namely Asoprinil,Ulipristal acetate have been 
introduced. 
Mirena is useful only in small fibroids without distortion of cavity. 
GnRH analogues are effective in shrinking fibroids and greatly improving 
menstrual symptoms but are limited by their side-effect profile especially 
osteoporosis and unpleasant menopausal symptoms. If given for 6 months, they 
reduce the fibroid volume by 30% and total uterine volume by 35%.They are only 
a short term solution for symptoms. 
Advantages of medical treatment
21
: 
 Avoids anesthesia and surgical risks. 
 Cures menorrhagia, controlsanemia, cures pressure symptoms. 
 Reduces the size of the tumor and blood supply, can be used preoperatively 
and allows use of laparoscopic myomectomy. 
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DISADVANTAGES: 
 Side effects like hot flushes, vaginaldryness, transient frontal headache, 
arthralgia, decreasedlibido, and osteoporosis limit the duration of use. 
 Failure of treatment. 
 Recurrence of symptoms and regrowth after stoppage of treatment. 
 Expulsion rates of LNG-IUS are higher in women with fibroids. 
 Surgery may still be required. 
 
MINIMALLY INVASIVE PROCEDURES: 
LAPAROSCOPIC GUIDED MYOLYSIS AND CRYOMYOLYSIS
19
: A number of 
energy sources using bipolar electrosurgery, Nd: YAG laser and cryogenic probes 
were used under laparoscopic direction to reduce fibroid size by means of fibroid 
destruction and interference with local vascular supply. 
Advantages: 
 Ease and rapidity of surgery. 
 Good hemostasis. 
 Rapid recovery. 
Disadvantages: 
 Delay in reduction of uterine size 
 Great risk for recurrence. 
30 
 
 
DEFINITIVE LINE OF MANAGEMENT: 
The definite line of management for fibroids traditionally include various surgical 
procedures viz, myomectomy and hysterectomy. In recent years myomectomy is 
being done through minimally invasive techniques like laparoscopic and 
hysteroscopic myomectomy. 
MYOMECTOMY: 
Myomectomy should be considered a safe alternative to hysterectomy. VICTOR 
BONNEY stated in 1931 that ―THE RESTORATION AND MAINTENANCE OF 
PHYSIOLOGIC FUNCTION SHOULD BE THE ULTIMATE GOAL OF 
SURGICAL TREATMENT.” 
Myomectomy whilst aiming to preserve fertility is also associated with morbidity 
and hospital stay and carries the risk of proceeding to emergency hysterectomy
21
. 
In addition it may also compromise reproductive potential and provide difficulties 
in long term management owing to high recurrence rate of fibroids and adhesion 
formation. Withmyomectomies, operating times were longer. Use of tourniquets, 
vasoconstrictiveagents, cell savers may be considered to limit the blood loss during 
myomectomy. 
ADVANTAGES: 
 Removes fibroids and cures symptoms in one sitting. 
 Improves fertility in 40% cases. 
31 
 
 
 Risk of malignancy eliminated. 
DISADVANTAGES: 
 Risks of anesthesia and surgery. 
 Postoperative adhesions. 
 Recurrence of fibroids due to growth of seedling fibroids. 
 Persistence of menorrhagia in 5 to 10% due to congestion enlarged uterine 
cavity. 
HYSTEROSCOPIC MYOMECTOMY:  
In recent years, hysteroscopic myomectomy being minimally invasive is gaining 
popularity.Hysteroscopic myomectomy has become possible in a sub mucous 
fibroid. 
Advantages: 
 Minimally invasive. 
 Lack of incision on the exterior of the uterus. 
 Reduces likelihood of pelvic adhesions. 
Disadvantages: 
 Inadvertent perforation of uterus. 
 Bleeding 
 Intracavitary adhesions. 
32 
 
 
 Hyponatremia, hyperammonemia and cerebral edema can occur with use of 
electrolyte poor solutions. 
LAPAROSCOPIC MYOMECTOMY: 
Laparoscopic myomectomy is feasible in: 
 A pedunculated fibroid. 
 Subserous fibroid not exceeding 10 cm in size and not exceeding 4 in 
number. 
Fibroid is retrieved through posterior colpotomy,minilaparotomy or morcellation. 
Laparoscopic myomectomy was associated with longer operating times, reduced 
postoperative anemia. Reduced postoperative pain and speedy recovery of patients. 
Disadvantages: 
 Increased chance of bleeding due to nonapplicability of hemostatic clamp. 
 Increased postoperative adhesions. 
 Recurrence due to unrecognized small fibroid. 
SURGICAL HYSTERECTOMY: 
The traditional treatment of symptomatic fibroids is surgical, namely hysterectomy 
and myomectomy, But in recent times, if hysterectomy is offered as the first and 
only treatment option some women choose to accommodate to symptoms and stop 
seeking treatment. Hysterectomy ensures complete resolution of all symptoms and 
33 
 
 
is associated with a high patient satisfaction rate. However it is also associated 
with significant morbidity, relatively long hospital stay and guarantees infertility. 
Complications of hysterectomy: 
 Hemorrhage. 
 Anesthetic complications 
 Trauma to bladder, ureter, bowel during surgery. 
 Wound infection. 
 Abdominal adhesions. 
 Thrombosis, pulmonary embolism. 
SEQUELAE OF HYSTERECTOMY: In general women who had hysterectomies 
have significantly worse scores on quality of life questionnaires than women 
diagnosed with hypertension, heart disease and arthritis.  
 Dyspareunia due to short vagina and ovarian adhesions to the vault. 
 Chronic pelvic pain due to adhesions. 
 Residual ovarian syndrome and ovarian cancer in 1% of left behind ovary. 
 Vault prolapse. 
 Granulation tissue at the vault requiring treatment. 
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RECENT ADVANCES IN THE TREATMENT OF FIBROIDS: 
UTERINE ARTERY LIGATION: Recently the surgical ligation of uterine arteries 
has been performed and evaluated.46% decrease in fibroid volume has been 
observed and symptomatic improvement was noted. 
UTERINE ARTERY EMBOLISATION: 
In 1991, Ravina first performed uterine artery embolization. The goal is to deliver 
particulate material-typically polyvinyl alcohol particles into both arteries to 
produce ischemic changes to myoma without causing permanent damage to the 
uterus. 
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Contraindications: 
 Subserous and pedunculated fibroids 
 Sub mucous fibroid. 
 Infertility and desire of pregnancy. 
Advantages: 
 No major surgery. 
 No intraoperative bleeding. 
 Short hospital stay. 
Disadvantages: 
 Fever and infection. 
 Vaginal discharge and bleeding. 
 Ischemic pain suggests successful therapy but can be unbearable. 
 Pulmonary embolism. 
 Ovarian failure following accidental ovarian vessel blockage. 
 Fertility rate is reduced due to adhesions. 
MAGNETIC RESONANCE GUIDED FOCUSSED ULTRASOUND 
THERAPY: 
With the evolution of minimally invasive surgical and nonsurgical techniques and 
changing attitudes towards uterine preservation, the popularity of conservative 
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treatment options has escalated over the last decade. The noninvasive nature of 
MRgFUS holds particular attraction to women who intend to preserve the uterus. 
Though ultrasound imaging is classicallyrecognized as a diagnostic device, it was 
initially applied as a therapeutic rather than a diagnostic model. The use of 
ultrasound for medical ablative treatments has been recognized since 1920s.But 
limitations in accuracy and temperature monitoring hampered clinical development 
of this technique. 
PRINCIPLES: 
The principles of thermal ablation are that the application of heat leads to a                        
localized tissue destruction. Since the resulting cell necrosis is a coagulative rather 
than ischemic necrosis, the painful infarction syndrome which is recognized after 
uterine artery embolization is avoided. In 2004, the U.S. Food and Drug 
Administration (FDA) approved the use of Focused ultrasound under Magnetic 
resonance guidance in the cure of uterine leiomyomas.
43
 The feasibility of an MRI 
guided system was first described in 1995. Ultrasound waves of high intensity can 
be focused into a minimum volume of tissue to create an increase intemperature 
adequate enough to cause cell necrosis to the target that is deep in the body. 
“Imagine using a magnifying glass to focus the sun’s rays on a single point to 
create a flame to burn a leaf”.Just like that pulses ofenergy are repeated forentire 
37 
 
 
volume of fibroid.
 
Thus MRgFUS is a completely NONINVASIVE low risk therapy for treating 
uterine fibroids. It‘s like ‗TAKING CORE OF AN APPLE WITHOUT 
CUTTING IT OPEN.’ 
CONCURRENT MR IMAGING ALLOWS: 
 3-D anatomical information for exact tumor targeting. 
 To visualize the entire beam path such that the treatment would be safe. 
 To apply real time temperature monitoring to accomplish an outcome as 
intended. 
 Post treatment contrast imaging to evaluate the effectiveness of the therapy. 
The significant disparity between FUS and other forms of energy like radiotherapy 
is that the passage of ultrasound energy through intervening tissue has no apparent 
cumulative effect on that tissue. 
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The thermoablative element of MRgFUS ensues when numerous sound waves 
arising from an ultrasound source move across thedesired tissue andcongregate at a 
focal point in the target. Each individual burst of FUS energy is termed a 
sonication. Heating the tissue to more than 70 
o
C will lead to tissue damage by 
inducing coagulative necrosis.
45
 Tissue destruction is effectively accomplished 
through heat and cavitation effects by mounting up energy of high intensities in 
minimal volume of target tissue. 
Normally ultrasound energy passes throughwithout causing any harm to the 
interveningtissue. This is because very minimal amounts of energy are absorbed 
and this absorbed energy is usually dissipated by the cooling effects of perfusion 
and conduction. If, conversely, the ultrasound waves carry an excessive level of 
energy and areconverged to a tight focus, an increase in temperature would be 
observed, since the energy conveyed by the beam would be swiftly converted into 
heat.  
By rising the temperature to greater than 55 degree Celsius at the target point, the 
ultrasound waves can produce protein denaturation and thus end up in cell death. 
The resultant lesion of coagulative necrosis would be cigar shaped [3].  
Theother surrounding tissues and the tissues through which the ultrasound beam 
crosses other than the target focus ,are just warmed but are not heated upto lethal 
temperatures and are thus not damaged even minimally. 
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As the temperature rises, there occurs a shift in proton resonant frequency and this 
can be recognized with the use of phase imaging
46
. When successive phase-
shiftMR images acquired during each ultrasound sonication are evaluated and 
compared with the image taken just prior to that sonication, a real time thermal 
mapping of the rising temperature at the target and in the tissues surrounding the 
target can be generated by calibrating the changes in the recent images 
47
. 
 
 
The MRI-guided focused ultrasound therapy system utilized assimilates 
completely with a 1.5-T MRI system such that the focused ultrasound therapy 
applied can be programmed instantly with the MR images and real-time MR 
thermometry feedback of every sonication can be obtained. 
The ultrasound waves are generated from a piezoelectric plate contained within the 
transducer. Depending upon the size, shape and frequency of the ultrasound 
source, the generating ultrasound field is altered.
2
 .Focusing of the ultrasound 
waves, can be done using lenses or reflectors, or by converting the transducer into 
a self-focusing one. 
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TREATMENT PLANNING                                TREATMENT 
 
 
There is a computer-controlled positioning system, an amplifier system, and a user 
interface that are integrated with a MR imaging system (standard is 1.5 T). The 
lateral position and angle of the transducer can be mechanically controlled, and 
with beam steering the focusing depth and size of target focus can be controlled. 
[4]With this equipment ultrasound waves of high-intensity can be converged to a 
very minimal focal volume of tissue. The volume of destruction through ablation 
after each sonication pulse is very small, that is around 6 mm to 25 mm, and so 
numerous successive sonications are needed to create the desired effect.  
Large temperature elevations and persistence of this high temperature for a 
sufficient period is necessary to create tissue damage
44
. The exposure of the target 
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point to this high temperature must exceed beyond a threshold time for optimal 
thermal damage. The tissue might recover when either of these does not exceed the 
threshold. Desired necrosis would occur when the heating results in a temperature 
more than 50 
o
C and the same lasts for 10 seconds. Raising the temperature to 
higher degrees reduces the time required for necrosis. 
Thus a temperature of 56 
o
C would need only 1 second for necrosis and elevating 
the temperature to 60 
o
C reduces the time for necrosis to 0.1 second. On the 
contrary, a temperature of 45 
o
C will need a longer time as 1000 seconds to result 
in necrosis. Henceforth the desired result of coagulation necrosis can be obtained 
when the heating is increased to the appropriate temperature and is sustained for 
the threshold time, by producing protein denaturation and cell death. However, the 
tissues other than the focus which lie in the  path of the ultrasound beam, are just 
warmed, only to  temperatures that are sublethal.Achieving the  optimal 
temperature elevation is influenced by many factors,viz,the type of tissue, the size, 
shape of the ultrasound beam, the presence of high vascularity which act as a heat 
sink
44
. 
The other effect caused by focused ultrasound is an acoustic cavitation effect
44
. In 
this effect, acoustic energy is concentrated in small gas bubbles that are generated 
by the energy from the ultrasound. This results in a substantial increase in the 
42 
 
 
absorption of ultrasound energy in tissue. Major tissue destruction might occur due 
to violent bubble collapse leading to significant energy release in the vicinity. 
Enhancing the area of ablated volume during each sonication can be achieved 
through controlled micro bubble formation
49
. Thus with each sonication the 
resultant Nonperfused volume obtained would be higher. 
MRI Temperature Measurement Principles:. 
 MRI has tremendous soft-tissue contrast and the capacity to generate immediate, 
quantitative temperature imaging in a range of tissues
46,47
. Temperature 
measurement in MRI can be done with an array of techniques: apparentdiffusion 
constant of water, the spin-lattice relaxation time, and the water proton resonance 
frequency shift (PRF). In response to changes in temperature,the proton resonance 
frequency of water changes. 
The images are used to construct the temperature images acquired during the 
sonications. They are compared with a reference image obtained just prior to the 
sonications to create a real-time thermal map. Thus it helps us to monitor the 
temperature changes in the area of region of treatment. 
 
BENEFITS: 
The major benefits to the society are: 
 Uterus sparing Noninvasive therapy  for  Fibroids 
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 Fast Outpatient Procedure 
 High patient compliance 
 Short recovery time. Return to normal activity in 1 to 2 days. No loss of 
work days. 
 Safe and effective procedure, very rare complications. 
 No Anaesthesia,No radiation, Noscars, No hospital stay 
 Outpatient procedure – WALK-IN AND WALK-OUT PROCEDURE, no 
hospital stay. 
Thus MRgFUS therapy provides a potentially new noninvasive and effective 
treatment of fibroids.The total lack of invasiveness and the fact that it is performed 
as an outpatient procedure makes it very attractive for patients. 
  
MRgFUS offered women sustained relief from uterine fibroid symptoms for upto 
two years, with a low incidence of side effects, according to a study published in 
the August 2007 issue of Obstetrics and Gynecology. The 359-patient Mayo 
Clinic-led collaborative study also showed that destroying as much of the fibroid 
as possible leads to the most durable symptom relief with85% of the participants 
experiencing symptom improvement after one year. 
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FUTURE DIRECTIONS OF MRgFUS: 
 Large leiomyomas are difficult to treat with MRgFUS primarily because 
of the longer duration to complete the procedure.To solve this problem, 
we can pretreat the fibroids with GnRH agonists. Treatment for 6 months 
reduces the myoma volume by 30%
52
. 
 Desire for future fertility:If MRgFUS is able to decrease the size of the 
fibroid and allow for a more normal endometrial cavity, itis possible that 
fertility may be improved
53
. Since manypatients with large fibroids or 
multiple fibroids require an abdominal myomectomy, this noninvasive 
procedure should be the first option. An on-going trial is underway 
forpatients with symptomatic uterine fibroids who desire pregnancy after 
undergoing MRgFUS treatment.
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 Other applications: There are studies investigating the use of MRgFUS in 
adenomyosis, breastcancer, prostatecancer, braintumours and in drug 
delivery systems. 
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MATERIALS AND METHODS: 
 
PLACE OF STUDY: 
The study was conducted in the Institute of Social Obstetrics, Govt Kasturba 
Gandhi hospital Chennai in collaboration with theDepartment of Radiology and 
Imaging, Bharat Scans, between January 2012 and December 2012 over a period 
of 12 months. 
TYPE OF STUDY: 
         Prospective study. The study was submitted to the scientific and ethical 
committee and was approved. 
INCLUSION CRITERIA: 
Patients who presented  with symptomatic fibroids
49
 more than 18 years of age and 
who would have alternatively been offered traditional semi invasive or surgical 
treatment were selected for MRI guided focused ultrasound therapy.  
EXCLUSION CRITERIA: 
1. Women with asymptomatic fibroids 
2. Patients who were unsuitable for MRI. (Cardiac pacemakers,vascular clips 
etc.,) 
3. Patients with serious systemic diseases. 
4. Patients who weigh more than 150 kgs. 
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5.  Fibroids more than 10 cm. 
6. Patients with pedunculated fibroids with a slender stalk. 
7. Patients who were pregnant during the procedure. 
8. Patients with unmanageable bowel interposition and scars. 
9. Deep seated fibroids. (> 13 cm from the anterior abdominal wall). 
10. Fibroids with dense calcifications. 
METHODS OF ENROLLMENT: 
All patients who visited the Gynaec.O.P.Department at our institute were screened 
to verify who met the eligibility criteria
49
. They were sorted out and were 
thoroughly counseled regarding the procedure, the adverse effects that can occur 
during and after the procedure and after getting proper informed consent, they were 
included in the study. 
 The next step was to screen them for MR compatibility like excluding cardiac 
pacemaker, metallic implants and severe claustrophobia. The patient must be able 
to lie prone for about 3 hours and must be able to communicate sensations during 
the procedure. Importance was given to scars in the abdomen, as they may disrupt 
the passage of US waves. In our study, all suitable subjects were given 
questionnaires for symptom severity scoring which were assigned a score on a 4 
point scale. No symptoms-score 0, Mild symptoms-score 1, moderate symptoms-
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score 2, severe symptoms-score 3.These are subjective measurements for 
evaluation and monitoring. 
 
PREPROCEDURE MRI: 
 All patientsunderwent a screening MRI of the pelvic region to assess the anatomic 
suitability of the therapy.T1W and T2W images were obtained in axial, coronal 
and sagittal planes. Skin surface was included in the coronal plane to assess the 
position of scars intervening the beam pathway. It was done with patients in prone 
position so that images obtained mat resemble as those of treatment. 
The purpose of this screening MRI was: 
 To confirm the diagnosis. 
 To exclude associated adenomyosis, adnexal mass. 
 To assess the exact number of fibroids, size, location and enhancement 
characters. 
Small fibroids <3cm and large fibroids >10 cm were excluded due to the lack of 
ability to focus them or attain ideal necrosis. 
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Other Parameters to be assessed in MR imaging: 
 The path of Ultrasound beam: If fibroid was >12cm from the anterior 
abdominal wall, US waves may not penetrate the target. If it is very close to 
the sacrum, increasing the temperature of the sacral bone might end up with 
sciatic nerve injury. Sonications must be limited to at least 4cm from the 
sacral bone. Allinterposing or contiguous organs in the path of treatment as 
well as scars must be avoided. 
 Character of fibroids: There are two classes of fibroids45.Classical fibroids 
are those with low signal on all pulse sequences and enhance 
homogenously.Hypercellular ones are those with high signal, highly 
vascularized and are difficult to treat and they have a poor outcome. 
 Ideal patient is one with 
Anterior fibroid with uniform to low signal intensity, no intervening organ in 
pathway and with good perfusion. 
 
MRgFUS PROCEDURE: 
The MRI-guided focused ultrasound therapy systems used in this study PHILLIPS 
Sonalleve MR HIFU integrates with Achieva 1.5 T MR system to enable focused 
ultrasound therapy to be planned directly with MR images and to give real-time 
MR thermometry imaging after each sonication. 
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PREPROCEDURE PREPARATION: 
 Patients were instructed to fast at least for 6 hours before the procedure. 
Ideal would be fasting for 12 hours. 
 Abdomen was cleaned well and shaved from the xiphy sternum to one cm 
below the pubic bone to avoid any air bubbles trapped in hair which may 
increase the risk of burns. 
 Conscious sedation with midazolam was given to alleviate anxiety and pain 
such that the patient was responsive throughout. 
 Informed oral and written consent was obtained from all the participants 
after proper counseling about the procedure. 
 Continuous bladder drainage was kept to keep the bladder empty because 
filling of the bladder during the procedure may dislodge the uterus and alter 
the location of leiomyomas. 
 Patient was given a PANIC BUTTON during treatment such that she can 
stop the treatment when she has severe pain or heat sensation. 
 
 
 
TREATMENT PLANNING: 
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Patient was made to lie down in prone position such that her abdomen was 
in contact with acoustic gel pad in a water bath of degassed and deionized water. 
Prior to initiating the procedure multilane T2Wimages were taken and transferred 
for  planning workstation. Region of treatment (ROT) was manually drawn and 
outlined confiningwithin the capsule of the fibroid. 
Treatment areas were selected as small cells (Fig 2) of varying sizes ranging 
from 4mm to 32mm. Each cell was checked for safety in near field and far field. 
The cells were arranged in different clusters to cover the treatment area. (Fig 3) 
 
 
FIG 2. IMAGE SHOWS SAGITTAL SECTION IN PLANNING PHASE WHERE CELLS ARE 
ARRANGED   IN THE TREATMENT AREA AND THE TRANSDUCER OVERLAY CAN BE SEEN 
AS ANGLED BEAM. 
52 
 
 
Target volume was analyzed with superimposed US beam paths in 3 planes. The 
beam path must be angled for optimal access of the fibroid such that scars, air 
bubbles and other intervening organs are avoided. If fibroid was close to the 
serosal surface, a 0.5cm margin of no targeted tissue should be maintained to 
prevent thermal damage to tissues in close proximity. 
 
TEMPERATURE IMAGING: 
Source of signal in MR are the chemical environment and relaxation properties of 
nuclei. It is sensitive to tumbling of molecules and thus sensitive to temperature. 
There are three parameters for thermal imaging, of which the most appropriate is 
the shift in proton resonance frequency which yields quantitative temperature 
monitoring. Proton resonance frequency has linear relationship with changes in 
temperature. Except for adipose tissue, it is tissue independent and is not affected 
by tissue coagulation.Thermal images were obtained during every sonication in all 
three planes with phase subtraction fast gradient echo proton resonance frequency- 
shift- dependent techniques
46
.
 
PROCEDURE: 
After thermal imaging and marking the region of treatment, the procedure was 
initiated with delivery of subtherapeutic doses of low power sonication (50-100W) 
to the center of fibroid
54
. Real time thermometry was acquired through proton 
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resonance frequency shiftmethod. The consequential  images were offered for 
sonication location, to reassure the precision and accuracy of targeting. 
 
.  
 
 
 
 
 
IMAGE SHOWS THE PLANNING SEQUENCE IN ALL PLANES.THE TREATMENT CELLS APPEAR 
CIRCULAR PERPENDICULAR TO THE BEAM AND THEY ARE ―CIGAR SHAPED‖ PARALLEL TO THE 
BEAM. 
A pre sonication image obtained was used as baseline and further images were 
added sequentially in a single sonication. Colorcoding (Blue to red scale) (Fig 4) 
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representing the gradual increase in temperature were projected over the treatment 
area. Special graph showing the temperature rise was also made available on the 
screen. Next sonication was done after the lapse of reasonable cooling time. The 
sonication parameters were safely adjusted using the thermometry graphs for 
further safe sonications. 
 
Fig 4. TEMPERATURE MAPPING SEEN AS COLOR CODES FROM BLUE TO RED. 
 
 
Subsequent sonications were given at therapeutic power level. Until therapeutic 
thermal dose, energy delivered was increased to coagulate the tissue at 
temperatures above 60
o
 C.It is desirable to try and reach 70-80
o
C that ensures 
tissue necrosis. Each sonication lasts for 20-40seconds.Between each sonication 
sufficient cooling time should be given of upto 90seconds to avoid thermal buildup 
which will damage the surrounding tissues. 
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For all planned sonications the same procedure was continued. To be sure of no 
complications,constant interactionwith the patient wasimperative. The whole 
procedure would last for 3-4 hours.  
 
Criteria to terminate early were: 
 Failure to visualize focal treatment spot. 
 When the patient complaints of unbearable pain. 
 Targeting difficulties due to patient motion. 
After completing all the planned sonications, the last step was to assess the 
NONPERFUSED VOLUME by giving intravenous gadolinium as contrast. 
 
POSTPROCEDURE: 
Following the procedure, the patient was taken to a holding area where the Foley‘s 
catheter was removed. The skin surface would be examined for any heat induced 
changes. Body temperature would be recorded. Patient would be instructed not to 
drive and to take rest till she recovers from the sedation. She can resume activities 
the following day. The most common symptom was mild back pain, fever and 
general discomfort. Patient was discharged after one to two hours observation after 
the procedure. 
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FOLLOW UP OF PATIENTS: 
Patients were asked to come for follow up after 6 months and 12 months. They 
were given the same questionnaires regarding the improvement of symptoms. 
Their Hematocrit was measured and the values were noted. The fibroid shrinkage 
was assessed by clinical examination and Ultrasound pelvis. 
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REPRESENTATIVE CASES: 
Case 1:   Image (Left) - T2W preprocedure 
image showing a predominantly T2 
hypointense anterior wall fibroid.  Image 
(Right) – T1W post contrast image showing 
the non perfused area.            
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Case 2: Image (Left) - T2W preprocedure image showing a predominantly T2 
hypointense anterior wall fibroid.  Image (Right) – T1W post contrast image showing 
nearly 75%non-perfused volume.    
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Case 3 : 52 year female who presented with menorrhagia pre and post procedure post 
contrast images showing the treated volume. 
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Case 4:41 year female who presented with frequent micturition, pre and post 
procedure post contrast images showing the T2 heterointense fibroid. 
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Results and 
analysis  
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RESULTS 
Demographic Data: 
A total of 30 patients who underwent MR Guidedfocused ultrasound therapy for 
fibroids at Bharat Scans between January 2012 and December 2012 over a period of 
12 months, who fit the inclusion criteria were enrolled in this study. They underwent 
a preliminary screening MRI and those who were found to be eligible on screening 
were included in the study. 
The parameters measured were: 
 Hematocrit. 
 Menorrhagia scoring. 
 Dysmenorrhea scoring. 
 Pressure symptoms scoring. 
 Immediate Nonperfused volume 
 Fibroid volume and fibroid shrinkage. 
These parameters were measured at 6months and at the end of 12 months. The 
efficacy of MRgFUS was defined as improvement in the haematocrit, symptom 
scoring and attaining >50%Nonperfused volume. Continuous data were represented 
by mean and standard deviation and categorical data were represented by frequencies 
and percentages and were analysed. A value of p <0.05 was considered to be 
statistically significant. Data‘s were analysed with SPSS 14.0 version. 
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TABLE – 1 
AGE DISTRIBUTION OF FIBROIDS 
Age Group No. of Cases Percent 
21 – 30 2 6.7 
31 – 40 10 33.3 
41 – 50 16 53.3 
50 and above 2 6.7 
 
 
Table 1 demonstrates age wise distribution of the sample size. Highest prevalence  
 
was observed between age  41 - 50 with 53.3% of patients which is consistent with  
 
the incidence of fibroids. 
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64 
 
 
TABLE 2 
 
FIBROID VOLUME DISTRIBUTION 
 
  
Fibroid volume range(cm
3 
) 
No. of Fibroids 
< 100 5 
100 – 200 10 
200 – 300 11 
> 300 4 
 
 
 
 
Table 2 shows the distribution of fibroids as per their fibroid volume range. It was 
found that around 21 fibroids were in the range between 100 and 300 cm
3.
 
  
5
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TABLE – 3 
HEMATOCRIT PARIED SAMPLE STATISTICS 
  Mean  N  Std. Deviation Std. Error 
Pair - I HCT – Bef 28.40 30 2.207 0.403 
 HCT – 6 mnths 31.30 30 2.231 0.407 
Pair – II HCT – Bef 28.40 30 2.207 0.403 
 HCT – 12 mnths 33.07 30 1.964 0.359 
 
Table 3 shows the mean baseline hematocrit and the gradual increase in the mean 
hematocrit at 6months and at 12 months after treatment. It has increased from 28.4 to 
33.07. 
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PAIRED SAMPLE TEST FOR HEMATOCRIT 
 
 
   
  Mean  Std. 
Deviation 
Std. Error Mean p value 
Pair - I HCT – Bef 
-2.900 1.296 0.237 < 0.001 
 HCT – 6 mnths 
Pair – II HCT – Bef 
-4.667 1.845 0.337 < 0.001 
 HCT – 12 mnths 
 
The paired sample test between the hematocrit values before and after treatment at 6 
months and 12 months showed a statistically significant increase with a p value of 
<0.001. 
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TABLE 4, 
MENORRHAGIA SCORING – PAIRED SAMPLE STATISTICS 
  Mean  N Std. Deviation Std. Error 
Mean 
Pair - I Men Score – Bef 1.60 30 0.968 0.177 
 Men score – 6 
months. 
0.40 30 0.563 0.103 
Pair – II Men score – Bef  1.60 30 0.968 0.177 
 Men score – 12 
months 
0.17 30 0.379 0.069 
 
Table 4 shows the mean menorrhagia score before and after treatment at 6 months 
and 12 months. There was a significant decline in the scoring with 
symptomimprovement. 
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PAIRED SAMPLES TEST 
  Mean  N Std. 
Deviation 
Std. Error 
Mean 
P 
value 
Pair - I Men score – Bef 
1.2 30 0.664 0.121 <0.001  Men score – 6 
months. 
Pair – 
II 
Men score – Bef  
1.433 30 0.817 0.149 <0.001 
 Men score – 12 
months 
 
The paired sample test between the mean menorrhagia scoring before and after 
treatment at 6 months and 12 months was done and was found to be statistically 
significant with a p value <0.001. 
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TABLE 5 
DYSMENORRHEA SCORING 
  Mean  N Std. Deviation Std. Error 
Mean 
Pair - I Dys Scoring – Bef 2.13 30 0.629 0.115 
 Dys scoring– 6 
months. 
0.80 30 0.714 0.130 
Pair – II Dys scoring– Bef  2.13 30 0.629 0.115 
 Dys scoring – 12 
months 
0.27 30 0.450 0.82 
 
 
Table 5shows the mean dysmenorrhea score before and after treatment at 6 months 
and 12 months. There was a significant decline in the scoring with symptom 
improvement. 
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PAIRED SAMPLE TEST FOR DYSMENORRHEA SCORING 
 
  Mean Std. Deviation 
Std. Error 
Mean 
P value 
Pair - I Dys – Bef 
1.333 0.479 0.088 <0.001 
 Dys – 6 months. 
Pair – II Dys – Bef  
1.867 0.434 0.079 <0.001 
 Dys – 12 months 
 
 
The mean baseline dysmenorrhea scoring decreased from 2.13 to 0.27.The paired 
sample The paired sample test between the mean dysmenorrhea scoring before and 
after treatment at 6 months and 12 months was done and was found to be statistically 
significant with a p value <0.001. 
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TABLE 6 
PRESSURE SYMPTOMS PAIRED SAMPLE STATISTICS 
  Mean  N Std. Deviation Std. Error 
Mean 
Pair - I Press symptoms 
scoring – Bef 
1.10 30 0.960 0.175 
 Press symptom 
scoring – 6 months. 
0.53 30 0.776 0.142 
Pair – II Press symptom 
scoring – Bef  
1.10 30 0.960 0.175 
 Press symptom 
scoring – 12 
months 
0.50 30 0.731 0.133 
 
 
Table 5 shows the mean dysmenorrhea score before and after treatment at 6 
 
months and 12 months. There was a significant decline in the scoring with symptom  
 
improvement. 
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PAIRED SAMPLE TEST 
 
 
 
 
 
  Mean Std. Deviation 
Std. Error 
Mean 
P value 
Pair - I Press sympt.- Bef 
0.567 0.568 0.104 <0.001  Press sympt.- 6 
months 
Pair – II Press sympt.- Bef 
0.600 0.563 0.103 <0.001  Press sympt.- 12 
months 
 
 
 
The mean baseline pressure symptom scoring decreased from1.10 to 0.5. The paired 
sample test between the mean pressure symptom scoring before and after treatment at 
6 months and 12 months was done and was found to be statistically significant with a 
p value <0.001. 
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TABLE 7 
MASS EFFECT CROSS TABULATION 
  Mass Effect After Total 
No Yes 
Mass effect Before 
No 12 0 12 
Yes 8 10 18 
 Total 20 10 30 
 
 
 
 
Table 7 shows that out of 18 people who had mass effect before treatment, 8 were  
relieved of the symptom. But 10 of them had persistent symptoms. 
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TABLE 8 
DISTRIBUTION OF IMMEDIATE NONPERFUSED VOLUME 
 
NPV Ratio (Immed.) Mean No. of fibroids percentage 
< 40% 30.66 9 30 
40 – 60% 50.53 13 43.3 
> 60% 65.75 8 26.7 
 
 
 
Table 8 shows the distribution of NPV Ratio. Out of 30 patients treated, 43.3% of  
 
them attained between 40 and 60 % NPV Ratio, with a mean value of 48.98% 
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TABLE 9 
FIBROID SHRINKAGE AND NPV 
FIBROID SHRINKAGE 
NPV 
<40% 41-60% > 60% 
< 15%  1 100% 0  0  
16 – 30% 8 80% 2 20% 0  
> 30% 0  11 57.9% 8 42% 
 9  13  8  
 
 
CHISQUARE TEST 
 
 Value df Value 
Pearson chi-square 22.918 4  
Likelihood ratio 28.690 4 < 0.001 
Linear by linear Association 17.122 1  
 
Table 9 shows that all fibroids that had a NPV ratio of >60% had a fibroid shrinkage 
of more than 30%.The values were analyzed with chi square tests and were found to 
have a significant p value of <0.001. 
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RELATION BETWEEN NPV RATIO AND FIBROID SHRINKAGE 
 
 
 
 
The above bar chart depicts that all 8 fibroids that had a NPV ratio of >60% and 
11 out of 13 fibroids that attained a NPV ratio of 40-60% showed a fibroid  
Shrinkage of >30%. 
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TABLE 10 
AGE GROUP AND NPV IMMEDIATE 
 
Age Group No. of cases < 40% 40 – 60% > 60% 
< 35 Yrs. 7 2 3 2 
36 – 45 Yrs. 16  3 8 5 
> 45 Yrs. 7  4 2 1 
Total 30 9 13 8 
 
Table 10 shows the distribution of NPV Ratio among different age groups. It is 
inferred that maximum NPV ratio is attained in the age group 36-45 years 
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TABLE 11. 
ACOUSTIC WINDOW AND NPV 
 
Age Group Total < 40% 40 – 60% > 60% 
No Interference 18 4 (44.4) 7 (53.8) 7 (87.5) 
Scar 6 4 (44.4) 2 (15.4) 0 (0) 
Interference 6 1 (11.1) 4 (30.8) 1 (12.5) 
Total 30 9 13 8 
 
 
Table 11 shows that 87.5% of patients who belonged to >60% NPV ratio had no 
interference in the beam pathway. 
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TABLE 12 
 
NUMBER OF FIBROIDS AND NPV 
 
No. of Fibroids Total 
NPV 
< 40% 40 – 60% > 60% 
Single 19 3 8 8 
Multiple 11 6 5 0 
Total 30 9 13 8 
 
 
CHI-SQUARE TEST 
 
 
 
 
 
 
 
 
Table12 shows the influence of the number of fibroids and NPV ratio. It shows that   
 
only single fibroids could attain a better NPV ratio. The analysis of the values gave  
 
a significant p value of <0.05. 
 
 Value Df P value 
Pearson Chi-
square 
8.139 2 0.017 
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NUMBER OF FIBROIDS AND NPV 
 
 
The bar chart depicts the relation between number of fibroids and NPV ratio. It was  
found that 100% of all fibroids that attained a NPV ratio of more than 60% were  
single fibroids.  
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TABLE 13 
SIGNAL INTENSITY AND NPV 
 
Signal Intensity 
of fibroid 
Total 
NPV 
< 40% 40 – 60% > 60% 
Low 22 3 11 8 
High 8 6 2 0 
Total 30 9 13 8 
 
 
CHI-SQUARE TEST 
 
 Value Df P value 
Pearson Chi-
square 
11.119 2 0.004 
 
Table 13 shows the influence of signal intensity of fibroids on T2 weighted MR 
Images. It is inferred from the table that low intensity fibroids attain a better NPV 
ratio. The values were analyzed and was found to be significant with a p value of 
<0.05. 
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Signal intensity of fibroid and NPV RATIO. 
 
 
 
The bar chart depicts the influence of signal intensity of fibroid with the NPV  
Outcome. It shows that 100% of >60% NPV was attained in low intensity  
fibroids, whereas 75% of high intensity fibroids attained NPV ratio of <40%. 
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TABLE 14 
MRgFUS AND ADVERSE EFFECTS 
 
FIBROID 
VOLUME 
NO. OF 
CASES 
COMPLICATIONS NO 
COMPLICATIONS 
FEVER BACK 
PAIN 
<100 5 0 0 5 
100-200 10 0 0 10 
>200 15 2 3 10 
 30 2 3 25 
 
 
Table 14 shows that out of 30 patients treated, five of them had minor adverse  
effects like fever and backpain.Adverse effects occurred in fibroids of volume  
>200cm
3 
. 
FEVER
BACKPAIN
NO …
0
1
2
3
4
5
6
7
8
9
10
<100
100-200
>200
0
0
2
0
0
3
5
10 10
N
U
M
B
ER
 O
F 
P
A
TI
EN
TS
FIBROID VOLUME
FEVER
BACKPAIN
NO COMPLICATIONS
84 
 
 
TABLE 15 
 
MRgFUS AND ANY ADDITIONAL TREATMENT 
 
 
ANY ADDITIONAL 
TREATMENT 
NO. OF FIBROIDS PERCENT 
YES 2 6.7 
NO 28 93.3 
 
 
 
Table 15 shows that out of 30 fibroids treated, two of them needed additional  
treatment of hysterectomy due to persistence of symptoms which comprised of 6.7%  
of fibroids treated. 
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DISCUSSION 
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DISCUSSION: 
This is a prospective study conducted at the Institute of Social Obstetrics-Govt 
Kasturba Gandhi Hospital in collaboration with BHARATH SCANS during the 
period 2011-2012. 
The purpose of this study was to assess the effectiveness of MRgFUS in the treatment 
of uterinefibroids. In our study we had 30 eligible patients with symptomatic fibroids 
who met the inclusion criteria and were enrolled after a preliminary MRI screening. 
Symptom severity scoring: 
Symptoms like menorrhagia,dysmenorrhea,pressuresymptoms and mass effect as 
reported by patients before,6 months and 12 months after treatment were assessed on 
a 4point scale with 0=none.1=mild,2=moderate and 3=severe. 
The mean baseline for SSS OF MENORRHAGIA was 
 At baseline:1.6 
 At 6 months follow up:0.4 
 At 12 months follow up:0.17 
The mean values for SSS of DYSMENORRHEA was 
 At baseline: 2.13 
 At 6 months follow up:0.80 
 At 12 months follow up: 0.27 
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The mean values for SSS of pressure symptoms were as follows: 
Pressure symptoms 
1. At baseline:1.10 
2. At 6 months follow up: 0.53                                         
3. At 12 months follow up: 0.50 
All the above mentioned SSS showed a decline and had a statistical significance with 
pvalue <.001, hence proving the hypothesis that MRgFUS treatment brings about 
significant and sustained improvement in symptoms. 
Stewart EA et al conducted a study in 2007 and concluded that the symptom severity 
scoring significantly reduced from the baseline as early as 3 months.
2 
 
Fenessey FM et al in 2007 showed that there was a significant 10 point improvement 
from baseline SSS score at the end of 12 months in those with NPV>30%
22
. 
Funaki K Sawadak et al in 2007 derived in his study of 63 patients that mean 
symptom scores were significantly reduced
35
. 
Rabinovici J Inbar Y Revel A et al in 2007 concluded that 69% of patients reported 
either significant or partial improvement in symptoms
36
. 
Gorny KR et al in 2011 conducted a study and showed that 92.9% of participants had 
symptom improvement at 6 months and 7.1% of them had no symptom relief
34
.  
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HEMATOCRIT: 
In our study there was a mean increase in hematocrit from the baseline which was 
attributed to significant reduction in menorrhagia. 
The mean values for hematocrit in our study: 
 Before:28.4 
 At 6 months:31.3 
 At 12 months:33.07 
There was a statistically significant increase in hematocrit from a mean of 28.4 to 
33.7 with a p value of <0.001. 
Stewart EA et al,Rabinovici in 2007 showed higher symptom improvement and 
improvement in hematocrit with higher NPV ratio
33
. 
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FACTORS INFLUENCING IMMEDIATE NPV 
SIGNAL INTENSITY OF FIBROID: 
In our study of 30 patients, we had 22 fibroids of low intensity and 8 fibroids of high 
intensity, 
100 percent of >60% NPV and 84.6 percent of 41-60% NPV were of low intensity 
fibroids. 
75percent of high intensity fibroids attained only <40% NPV.These values were 
coinciding well with a p value of <0.001. 
Ronit et al in 2011 showed that hypointense fibroids had a better odd‘s ratio for a 
better NPV Ratio. 
FunakiK, Fukunishi H.Funaki T et al in 2007 reported that the efficacy of MRgFUS 
correlates with the intensity of T2 weightedimages. Hypointense fibroids are suitable 
whereas hyperintense are not
44
. 
Lanard ZM, Fenessey FM et al in 2008 showed that fibroids with low intensity were 
more likely to shrink
55
. 
Mikami et al in 2008 reported that treatment was unsuccessful in 33% of patients due 
to high signal intensity of fibroids
56
. 
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NUMBER OF FIBROIDS: 
In ourstudy, out of 30 patients, 19 were single fibroids and 11 were multiple fibroids. 
100% of more than 60%NPV ratio was seen in single fibroids and 66.7% of <40% 
NPV ratio was seen in multiple fibroids. 
Analysis of values showed a significant p value of <0.05. 
ACOUSTIC WINDOW  
Among 30 patients in our study, 
18 patients had no interference in the acoustic window. 
6 patients had scars and 6 patients had some interference in the beam pathway lie 
bowel, other viscera... 
87.5% of >60% NPV ratio was attained only when there was no interference in the 
beam pathway.83% of NPV ratio <40% had some kind of interference in theform of 
scars, bowel or other viscera. 
Le Blang SD et al 2010 reported that factors limiting ablation were obstacles to 
passage of ultrasound beam like scars, bowel
39
. 
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NONPERFUSED VOLUME RATIO. 
The mean NPV ratio attained from a sample of 30 patients in our study is 48+ 
14%.This is influenced by many factors like signal intensity of fibroid, number of 
fibroids, depth of fibroids and interference in the acoustic window. 
The Immediate NPV ratio attained correlated well with the symptom improvement 
and fibroid shrinkage. 
Okada A et al in 2009 reported a mean NPV ratio of 46.6%
36
. 
GornyKR et al in 2011 showed an immediate NPV Ratio of 45.4%
38
. 
LeBlang SD et al in 2010 reported in his study a mean NPV ratio of 55%
39
. 
 
FIBROID SHRINKAGE 
In our study the mean shrinkage of fibroid by the end of 6 months was 32%.These 
values  correlated well with the IMMEDIATE NPV RATIO. 
The values were analyzedwith chi square tests and were found to have a significant p 
value of <0.05. 
Le Blang SD et al in 2010 reported in his study a mean fibroid shrinkage of 31%
39
. 
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LinYH, Leung TK, Wang HJ et al in 2009 showed that fibroid reduction by 6 months 
was 30.8%
57
. 
RenXL Zhang J et al in 2007 reported a mean reduction in size of fibroid of about 
49% by the end of 12 months
58
. 
 
ADVERSE EVENTS 
Out of 30 patients who underwent MRgFUS in our study, five of them reported 
minor adverse effects like fever, back pain. 
Two patients had fever which comprised of 6.6%. 
Three patients had back pain which comprised of 10% of patients. There was no 
incidence of skin burns, sciatic nerve palsy. 
Taran FA et al in 2009 reported in his study of incidence of 2.8% of fever
34
. 
Okada A et al in2009 reported post procedure adverse events as follows:
36 
Low back pain-8%, fever-6%, skin burns-1%, vaginal discharge-8%. 
Le Blang SD et al in 2010 showed that the incidence of minor skin burns was 2.5% 
and sciatica was 1.2%
39
. 
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ANY ADDITIONAL TREATMENT 
Among 30 patients in our study, twoof them opted out and went in for hysterectomy 
due to persistent symptoms especially because of  the mass effect since the size of 
uterus was more than 16 weeks. This comprises of 6.6%.The hysterectomy specimen 
showed vast areas of necrosis. 
Taran FA et al in2009 reported a treatment failure rate of 3.7%
34 
Okada A et al showed that the rate of alternative treatment by the end of 12 months 
was 5%
36
. 
Fenessey FM et al in 2007 showed that 28% sought alternative treatment
37
. 
Gorny KR et al in 2011 reported that additional procedures for fibroid related 
symptoms within 1 year was 6.2%
38
. 
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SUMMARY 
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SUMMARY: 
 The sample studied was 30 women with symptomatic fibroids. 
 Of these 19 had single fibroids and 11 had multiple fibroids. 
 22 were of low intensity and 8 were of high intensity fibroids on T2 weighted 
MR images. 
 There was a statistically significant decline in the symptom severity as per the 
symptom severity scoring for menorrhagia,dysmenorrhea,pressure symptoms 
and mass effect and pelvicdiscomfort. 
 There was a statistically significant improvement in the mean hematocrit.The 
mean hematocrit increased from 28.4 to 33.07 with a significant p value of 
<0.001. 
 The mean NPV ratio attained in our study was 48.63+14% which was 
comparable with that o other previous studies. 
 The mean fibroid shrinkage attained by 6 months was about 32% which 
correlated well with the immediate NPV Ratio with a significant p value 
<0.001. 
 Factors influencing NPV ratio were found to be signal intensity of fibroids, 
number of fibroids and any interference in the pathway of the ultrasound beam. 
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CONCLUSION 
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CONCLUSION 
MRgFUS has been tested and approved by the FDA and is a very successful 
noninvasive therapy particularly in those who demand a minimum treatment  
recovery time and for those who are unfit for anesthesia and surgery due to other 
comorbid medical illness. 
 From our study, there is evidence of improvements in the symptoms in patients 
treated with the MRgFUS, particularly for those presenting with symptoms of 
menorrhagia and dysmenorrhea. The symptom relief was sustained till one 
year. 
 Our study also showed a substantial improvement in the hematocrit following 
the procedure. 
 The mean fibroid shrinkage at 6 months correlated well with the immediate 
Nonperfused volume obtained. 
 In respect of safety, MRgFUS resulted in very minor adverse events like fever, 
abdominaldiscomfort, and backpain. There were no serious complications. 
 Women typically were able to return to their normal daily activities the 
following day. 
 In our study,there was no recurrence demonstrated and about 6.7% of them 
underwent  hysterectomy due to persistent pressure symptoms. 
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In conclusion, our data shows that MR-guided focused US is an effective 
technique to noninvasively and safely treat uterine leiomyomas in eligible 
patients, and it delivers significant and lasting symptom relief. 
 
LIMITATIONS OF OUR STUDY: 
  Smaller sample size  
  This sample population does not represent the true population.  
 Follow up period is 12 months and hence durability of symptoms could not be 
proved beyond 12 months. 
 Moreover there is no control group and whatever bias that may have existed in 
the patient selection is not known. 
Nonetheless the results are encouraging and further evaluation with different 
protocols is definitely warranted. 
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ABBREVIATIONS 
 
MRgFUS – Magnetic Resonance guided Focused Ultrasound 
HIFU-High Intensity Focused Ultrasound 
SSS – Symptom Severity Score 
USG – Ultrasonogram 
NPV – Non Perfused Volume 
MRI- Magnetic Resonance Imaging 
UAE- Uterine Artery Embolisation 
FUS-Focused UltraSound 
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1 Sarojini 40 839 30 8 NIL Single LOW 105 59 36 40 27 32 33 1 0 0 1 0 0 0 0 0 N N 65 1 NIL NIL 
2 Punithavathi 45 1691 32 10 INT Multiple LOW 135 68 61 25 33 36 36 0 0 0 1 0 0 0 0 0 N N 32 1 NIL NIL 
3 Yamuna 48 1213 32 10 NIL Single HIGH 185 79 68 28 28 33 35 3 1 0 2 1 0 2 2 2 Y Y 34 1 NIL NIL 
4 Suseela 45 1631 29 10 NIL Single LOW 165 88 77 44 31 33 36 1 0 0 2 0 0 0 0 0 N N 75 1 NIL NIL 
5 Sundari 32 664 25 10 NIL Single LOW 80 98 84 29 30 32 32 0 0 0 1 0 0 1 0 0 N N 42 1 NIL NIL 
6 Jayaseeli 29 1104 23 10 INT Multiple LOW 105 108 89 27 30 30 30 0 0 0 1 0 0 0 0 0 N N 33 1 NIL NIL 
7 Rajeswari 45 763 31 12 NIL Single LOW 190 123 101 37 28 30 32 1 0 0 2 1 0 0 0 0 N N 58 1 NIL NIL 
8 Poongothai 34 1056 28 12 NIL Single LOW 90 132 98 37 26 30 33 2 0 0 2 1 0 1 0 0 Y N 63 1 NIL NIL 
9 Sumithra 38 1605 28 12 NIL Single LOW 160 149 101 42 30 32 35 2 0 0 3 2 1 1 0 0 Y N 71 1 NIL NIL 
10 Nagalakshmi 45 479 30 14 INT Multiple LOW 145 161 104 29 28 30 30 3 1 1 3 2 1 3 1 1 Y N 41 1 NIL NIL 
11 Umarani 41 1607 31 14 NIL Single LOW 200 178 112 37 28 31 33 1 0 0 2 1 0 0 0 0 N N 56 1 NIL NIL 
12 Kalaiarasi 43 991 31 14 NIL Single LOW 170 182 119 34 30 33 33 1 0 0 2 0 0 1 0 0 Y N 42 1 NIL NIL 
13 Stella 48 1302 31 12 INT Single LOW 170 186 118 36 28 32 34 2 1 0 3 1 1 2 1 1 Y Y 43 1 NIL NIL 
14 Hemavathi 34 1276 25 12 NIL Single LOW 125 194 126 37 30 33 36 1 0 0 2 0 0 0 0 0 N N 62 1 NIL NIL 
15 Dhanam 45 1209 30 12 NIL Single HIGH 180 199 123 22 30 30 33 1 1 0 2 1 1 0 0 0 N N 27 1 NIL NIL 
16 Shamsudha 41 1502 32 12 INT Single LOW 210 212 138 28 29 33 36 2 0 0 2 1 0 1 0 0 Y N 38 1 NIL NIL 
17 Lalitha 40 1158 29 14 NIL Single LOW 150 229 147 36 33 36 36 1 0 0 2 0 0 1 0 0 N N 54 1 NIL NIL 
18 Nalina 23 1403 29 18 NIL Multiple HIGH 180 233 193 32 27 28 30 2 1 1 3 2 1 2 2 1 Y Y 46 2 NIL NIL 
19 Famidha 46 1305 33 14 NIL Multiple HIGH 130 235 152 24 27 32 32 3 1 1 3 2 1 1 1 1 Y Y 31 1 NIL NIL 
20 Mehboob 47 1134 33 14 ,INT Multiple HIGH 200 249 168 27 30 33 35 1 0 0 2 0 0 0 0 0 N N 33 1 NIL NIL 
21 Kamala 35 332 22 16 SC Multiple HIGH 165 252 182 13 25 28 30 3 2 1 2 1 0 3 2 2 Y Y 22 2 NIL Backpain 
22 Pushpa 48 1182 33 14 NIL Multiple HIGH 195 261 174 19 30 33 33 1 0 0 2 0 0 1 0 0 N N 26 1 NIL NIL 
23 Renuka 52 1257 31 16 NIL Single LOW 180 265 212 37 28 33 33 1 0 0 2 1 0 1 0 0 Y N 61 1 NIL NIL 
24 Saradha 43 1648 30 16 NIL Single LOW 180 274 192 38 30 32 33 1 0 0 2 1 0 1 0 0 Y N 68 1 NIL NIL 
25 Gandhimathi 42 1510 30 16 NIL Single LOW 135 288 216 34 27 30 33 1 0 0 2 1 0 1 0 0 Y N 46 1 NIL FEVER 
26 Shantha 40 467 29 18 SC Multiple HIGH 195 292 228 35 26 28 30 3 1 1 3 1 1 3 2 2 Y Y 57 2 NIL Backpain 
27 Gopika 44 1196 31 18 SC Single LOW 175 302 254 34 26 30 33 2 0 0 2 0 0 2 1 1 Y Y 61 1 NIL Backpain 
28 Buela 33 1007 26 20 SC Multiple LOW 220 304 221 33 24 27 31 3 1 0 3 2 1 2 1 1 Y Y 56 2 NIL NIL 
29 Kavipriya 40 1721 25 18 SC Single LOW 175 314 269 36 28 31 34 2 1 0 3 1 0 1 1 1 Y Y 59 2 HYST. NIL 
30 Sasikala 53 1227 30 20 SC Multiple LOW 200 326 265 33 25 28 32 3 1 0 2 1 0 2 2 2 Y Y 57 2 HYST. FEVER 
 
KEYTO MASTER CHART
Scoring system for pain:
None – 0
Mild – 1
Moderate – 2
Severe – 3
DYS – Dysmenorrhoea
MEN- Menorrhagia
PRESS – Pressure symptoms
HCT – Hematocrit
TOT – Total Score
FIN - Final
Bef – BeforeAft– After
HEM-HEMATOCRIT
HYST-HYSTERECTOMY
INT-INTERFERENCE
 
 
ANNEXURES  
PROFORMA
Name
Age
IP Number
Socio economic status
Address
Obstetric score
LMP:
Menstrual History: before/after
MENORRHAGIA-None/Mild/Moderate/Severe
DYSMENORRHEA- None/Mild/Moderate/Severe
Other symptoms: before/after
PRESSURE SYMPTOMS –None/Mild/Moderate/Severe
MASS EFFECT - yes/no
Marital History
Obstetric History
Past History
GENERAL EXAMINATION
Temperature
Pulse
BP
BMI
Anemia
Pedal edema
Breast
Thyroid
Spine
Per abdomen:
Presence of scars
Type of scar
Bimanual pelvic examination:
Size of uterus
Single/multiple fibroids
INVESTIGATIONS:
• Basic routine investigations esp Hematocrit—before/after
• Urine pregnancy test
• Ultrasound pelvis
• Colposcopy
• MRI pelvis
Fibroid volume
Numberof fibroids
Any interference in the acoustic window
Signal intensity of fibroid
gFjp II 
Ra xg;Gjy; gbtk; 
Ma;T nra;g;gLk; jiyg;G 
(MRI ];Nfd; cjtpAld; my;l;uhNrhdpf; mjph;Tfs; %yk; fh;gg;igapy; Vw;gLk;  
igg;uha;L vDk; fl;bia mfw;Wjy; njhlh;ghd Ma;T) 
 
Ma;T nra;Ak; ,lk;  : r%f kfg;Ngwpay; kw;Wk; muR f];J}hpgha;  
      fhe;jp jha;Nra; ey kUj;Jtkid> 
      nrd;id kUj;Jtf; fy;Y}hp> nrd;id 
gq;F ngWgthpd; ngah; : 
gq;F ngWgthpd; vz;; : 
gq;F ngWgthpd; taJ : 
gq;F ngWgth; ,jid (    ) Fwpf;fTk; 
 
 NkNy Fwpg;gpl;Ls;s kUj;Jt Ma;tpd;  tptuq;fs; vdf;F tpsf;fg;gl;lJ. 
vd;Dila re;Njfq;fis Nfl;fTk;> mjw;fhd jFe;j tpsf;fq;fis ngwTk; 
tha;g;gspf;fg;gl;lJ. 
ehd; ,t;tha;tpy; jd;dpr;irahfjhd; gq;Nfw;fpNwd;. ve;j fhuzj;jpdhNyh ve;j 
fl;lj;jpYk; ve;j rl;l rpf;fYf;Fk; cl;glhky; ehd; ,t;tha;tpy; ,Ue;J tpyfp 
nfhs;syhk; vd;Wk; mwpe;J nfhz;Nld;. 
,e;j Ma;T rk;ke;jkhf vd;Dila cly;epiy Fwpj;j jfty;fis Ma;T 
Nkw;nfhs;Sk; NghJ ,e;j Ma;tpy; gq;FngWk; kUj;Jth;> Ma;T Nkw;nfhs;Sk; epWtdk;> 
ed;elj;ij newpKiwfs; FO> xOq;FKiw Mizaq;fs; Mfpath;fs; fhz vd; 
KOkdJld; rk;kjpf;fpNwd;. ehd; Ma;tpypUe;J tpyfp nfhz;lhYk; ,J nghUe;Jk; vd 
mwpfpNwd;. 
,e;j Ma;tpd; %yk; fpilf;Fk; jfty;fisNah> KbTfisNah mwptpay; rhh;e;j 
NjitfSf;fhf gad;gLj;jpf;nfhs;s kWf;fkhl;Nld;. %zhk; egh;fSf;F jug;gLk; 
my;yJ gpuRhpf;fg;gLj; VNjDk; jfty;fspy; vd; jdpg;gl;l milahsk; 
ntspg;gLj;jg;glkhl;lhJ vdTk; ehd; Ghpe;J nfhz;Nld;. 
,e;j Ma;tpy; gq;F nfhs;s xg;Gf;nfhs;fpNwd;.  vdf;F nfhLf;fg;gl;l 
mwpTiufspd;gb ele;J nfhs;tJld; ,e;j Ma;it Nkw;nfhs;Sk; kUj;Jt mzpf;F 
cz;ikAld; ,Ug;Ngd; vd;Wk; cWjpaspf;fpNwd;. 
 
gq;Nfw;gthpd; ifnahg;gk; ……………….,lk; ……….…….Njjp 
fl;iltpuy; Nuit 
gq;Nfw;gthpd; ngah; kw;Wk; tpyhrk; …………………………….. 
Ma;thshpd; ifnahg;gk; ……………….,lk; ……….…….Njjp 
Ma;thshpd; ngah; ………………. 
  
 
INFORMED CONSENT FORM 
PART II 
STUDY TITLE 
PROSPECTIVE STUDY ON THE EFFECTIVENESS OF MAGNETIC RESONANCE GUIDED 
FOCUSED ULTRASOUND THERAPY IN THE TREATMENT OF UTERINE FIBROIDS 
 
STUDY CENTRE: Institute of social obstetrics, Govt. Kasturba Gandhi Hospital, 
   Madras Medical College, Chennai. 
Patient may check () these boxes 
 
PARTICIPANT NAME        AGE:     I.D.NO.  
 
I confirm that I have understood the purpose of the above study. I have the opportunity to ask the 
question and all my questions and doubts have been answered to my complete satisfaction. 
 
I  understand that my participation in the study is voluntary and that I am free to withdraw at any 
time without giving any reason. Without my legal rights being affected. 
 
I understand that investigator, the institution, regulatory authorities and the ethics committee will 
not need my permission to look at my health records both in respect to the current study and any 
further research that may be conducted in relation to it, even if I withdraw from the study. I 
understand that my identity will not be revealed in any information released to third parties or 
published, unless as required under the law. I agree not to restrict the use of any data or results that 
arise from this study. 
 
I hereby consent to undergo complete physical examination and diagnostic tests including 
hematological, biochemical, radiological and urine examinations  
 
I hereby consent to participate in this study of PROSPECTIVE STUDY ON THE 
EFFECTIVENESS OF MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND 
THERAPY IN THE TREATMENT OF UTERINE FIBROIDS 
 
Signature of the Patient:…………………..Place……………Date 
………………….. 
Address………………………………………………………………… 
Signature  of the Witness: …………………..Place……………Date…………… 
Signature  of the Investigator: ……………….Place……………Date…………… 
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